Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 4,768 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Branch II Clear all
Active, not recruiting Phase 2 Interventional

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

NCT04870762
View directory record Official record
Conditions
Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm, Maxillary Sinus Carcinoma, Nasal Cavity Carcinoma, Oral Cavity Carcinoma, Tongue Carcinoma, Tonsillar Carcinoma
Interventions
Best Practice, Medical Device Usage and Evaluation
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

NCT00033462
View directory record Official record
Conditions
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Nov 10, 2026, 9:41 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy

NCT02300727
View directory record Official record
Conditions
Mucositis
Interventions
Curcumin-MTD, Mouthwash-standard pharmacy preparation, Curcumin
Drug
Lead sponsor
Amy Beres
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Nov 10, 2026, 9:41 PM EST
Terminated Phase 2 Interventional

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

NCT01500161
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkins Disease, Non-Hodgkins Lymphoma, Aplastic Anemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Busulfan, Clofarabine, Fludarabine, Melphalan, Carmustine, Etoposide, Cytarabine
Drug
Lead sponsor
Texas Oncology Cancer Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 2 Interventional Results available

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

NCT01796197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial

NCT06697496
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
QuitBot Smoking Cessation Chatbot Program, QuitBot Smoking Cessation Text Messaging Program, Survey Administration, Interview, Carbon Monoxide Measurement
Device · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
772 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT00033553
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
74
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Nov 10, 2026, 9:41 PM EST
Recruiting Phase 2 Interventional

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

NCT07085039
View directory record Official record
Conditions
Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 2 Interventional Results available

L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

NCT01841281
View directory record Official record
Conditions
Asthma, Inflammation
Interventions
L-Arginine, Placebo
Drug
Lead sponsor
Nicholas Kenyon
Other
Eligibility
19 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Nov 10, 2026, 9:41 PM EST
Terminated Phase 2 Interventional Results available

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

NCT02774681
View directory record Official record
Conditions
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Cognitive Assessment, Palbociclib, Quality-of-Life Assessment, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Nov 10, 2026, 9:41 PM EST
Active, not recruiting Phase 2 Interventional

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

NCT04233866
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride, Leucovorin, Leucovorin Calcium, Liposomal Irinotecan, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
70 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
760
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 2 Interventional

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

NCT00044551
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Taxane (Cytotoxic, BAY59-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Miami Beach, Florida • Chicago, Illinois • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Nov 10, 2026, 9:41 PM EST
Active, not recruiting Phase 3 Interventional Results available

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

NCT03367702
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
276
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 3 Interventional Results available

Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00107172
View directory record Official record
Conditions
Lung Cancer
Interventions
surgery, brachytherapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
37
States / cities
Scottsdale, Arizona • Sacramento, California • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Nov 10, 2026, 9:41 PM EST
Terminated Phase 2 Interventional Results available

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00383565
View directory record Official record
Conditions
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Nov 10, 2026, 9:41 PM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 2 Interventional

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

NCT01409200
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Axitinib, Radical Prostatectomy, Regional Lymph Node Dissection
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer

NCT00102011
View directory record Official record
Conditions
Colorectal Cancer
Interventions
annual screening, fecal occult blood test, screening colonoscopy, standard follow-up care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years to 69 Years
Enrollment
4,952 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2026
U.S. locations
4
States / cities
Shreveport, Louisiana • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Completed Phase 3 Interventional

INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant

NCT01602211
View directory record Official record
Conditions
Cancer Survivor, Depression, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome
Interventions
Internet-Based Intervention, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Tampa, Florida • Detroit, Michigan • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 10, 2026, 9:41 PM EST
Recruiting Phase 2 Interventional

A Study of Ropeg-Interferon in People With Polycythemia Vera

NCT07886801
View directory record Official record
Conditions
Polycythemia Vera (PV), JAK2 Mutation
Interventions
Ropeginterferon
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824181
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Active, not recruiting Phase 3 Interventional

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

NCT01893307
View directory record Official record
Conditions
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 10, 2026, 9:41 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT04787744
View directory record Official record
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 9:41 PM EST